Literature DB >> 9396713

Endothelin attenuates apoptosis in human smooth muscle cells.

J R Wu-Wong1, W J Chiou, R Dickinson, T J Opgenorth.   

Abstract

An imbalance between proliferation and apoptosis is an important causal factor for disorders involving abnormal cell accumulation. Endothelin (ET)-1, a 21-amino-acid peptide with mitogenic and vasoconstricting activities, not only acts as a mitogen, but also attenuates paclitaxel-induced apoptosis in smooth muscle cells. In both human pericardial and prostatic smooth muscle cells, addition of ET-1 reduced paclitaxel-induced DNA fragmentation and phosphatidylserine on the cell surface, two characteristics of apoptosis. By comparison, angiotensin II, another vasoactive peptide, did not have a significant effect on apoptosis. The effect of ET-1 was dose-dependent with an EC50 of 1 nM. These results suggest that ET is a potential survival factor for smooth muscle cells, and that altered activity of the ET system in disease states has potential to contribute to aberrant cell growth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9396713      PMCID: PMC1218979          DOI: 10.1042/bj3280733

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  35 in total

Review 1.  Structure-function relationships of endothelins, sarafotoxins, and their receptor subtypes.

Authors:  M Sokolovsky
Journal:  J Neurochem       Date:  1992-09       Impact factor: 5.372

2.  Purification and characterization of bovine lung endothelin receptor.

Authors:  M Kozuka; T Ito; S Hirose; K M Lodhi; H Hagiwara
Journal:  J Biol Chem       Date:  1991-09-05       Impact factor: 5.157

3.  Cloning and expression of a cDNA encoding an endothelin receptor.

Authors:  H Arai; S Hori; I Aramori; H Ohkubo; S Nakanishi
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

4.  Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor.

Authors:  T Sakurai; M Yanagisawa; Y Takuwa; H Miyazaki; S Kimura; K Goto; T Masaki
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

5.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

6.  Endothelin is a potent mitogen for rat vascular smooth muscle cells.

Authors:  Y Hirata; Y Takagi; Y Fukuda; F Marumo
Journal:  Atherosclerosis       Date:  1989-08       Impact factor: 5.162

7.  Growth factor activity of endothelin on vascular smooth muscle.

Authors:  A Bobik; A Grooms; J A Millar; A Mitchell; S Grinpukel
Journal:  Am J Physiol       Date:  1990-03

8.  Selective antagonism of the ET(A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs.

Authors:  S E Burke; N L Lubbers; G D Gagne; J L Wessale; B D Dayton; C D Wegner; T J Opgenorth
Journal:  J Cardiovasc Pharmacol       Date:  1997-07       Impact factor: 3.105

9.  Cilazapril and early atherosclerotic changes after balloon injury of porcine carotid arteries.

Authors:  J Y Lam; L Lacoste; M G Bourassa
Journal:  Circulation       Date:  1992-04       Impact factor: 29.690

10.  Role of endothelin-1 in regulating proliferation of cultured rabbit airway smooth muscle cells.

Authors:  J P Noveral; S M Rosenberg; R A Anbar; N A Pawlowski; M M Grunstein
Journal:  Am J Physiol       Date:  1992-09
View more
  15 in total

1.  Pharmacological characterization of endothelin receptor subtypes in the guinea-pig prostate gland.

Authors:  W A Lau; S L Cox; J N Pennefather; F J Mitchelson
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 2.  Endothelium-derived ET-1 and the development of renal injury.

Authors:  Carmen De Miguel; David M Pollock; Jennifer S Pollock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-05-20       Impact factor: 3.619

3.  Modulation of human colon tumor-stromal interactions by the endothelin system.

Authors:  G Egidy; L Juillerat-Jeanneret; J F Jeannin; P Korth; F T Bosman; F Pinet
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

4.  Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse?

Authors:  Meejeon Roh; Sarki A Abdulkadir
Journal:  Cancer Biol Ther       Date:  2010-04-26       Impact factor: 4.742

5.  Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.

Authors:  D Salani; G Taraboletti; L Rosanò; V Di Castro; P Borsotti; R Giavazzi; A Bagnato
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

6.  Endothelin-1 inhibits apoptosis in prostate cancer.

Authors:  Joel B Nelson; Michael S Udan; Georgi Guruli; Beth R Pflug
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

7.  The endothelin system in Morris hepatoma-7777: an endothelin receptor antagonist inhibits growth in vitro and in vivo.

Authors:  Thiemo Pfab; Gisela Stoltenburg-Didinger; Christoph Trautner; Michael Godes; Christian Bauer; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

8.  Transgenic mice over-expressing endothelin-1 in testis transactivated by a Cre/loxP system showed decreased testicular capillary blood flow.

Authors:  Amy C Y Lo; Maggie K L Fung; C L Au; Theobald S K Chan; Brian Sauer; Stephen S M Chung; Sookja K Chung
Journal:  Transgenic Res       Date:  2004-04       Impact factor: 2.788

Review 9.  Endothelin-1 as a target for therapeutic intervention in prostate cancer.

Authors:  E Scott Kopetz; Joel B Nelson; Michael A Carducci
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

10.  Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles.

Authors:  Christine J Weydert; Alison K Esser; Ruth A Mejia; Justin M Drake; J Matthew Barnes; Michael D Henry
Journal:  Cancer Biol Ther       Date:  2009-04       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.